Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: Tertiary amides

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 3, 2004, Pages 797-800

  Chan, Laval ^a   Pereira, Oswy ^a   Reddy, T Jagadeeswar ^a   Das, Sanjoy K ^a   Poisson, Carl ^a   Courchesne, Marc ^a   Proulx, Mélanie ^a   Siddiqui, Arshad ^a   Yannopoulos, Constantin G ^a   Nguyen Ba, Nghe ^a   Roy, Caroline ^a   Nasturica, Daniel ^a   Moinet, Christophe ^a   Bethell, Richard ^a   Hamel, Martine ^a   L'Heureux, Lucille ^a   David, Maud ^a   Nicolas, Olivier ^a   Courtemanche Asselin, Philippe ^a   Brunette, Stéphanie ^a   Bilimoria, Darius ^a   Bédard, Jean ^a   more..

^a Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; GENOMIC RNA; NS5B POLYMERASE; NS5B POLYMERASE INHIBITOR; RNA POLYMERASE; TERTIARY AMINE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENCY; ENZYME INHIBITION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEAR OVERHAUSER EFFECT; RNA REPLICATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

HEPATITIS C VIRUS;

EID: 1642493633     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.068     Document Type: Article

References (12)

1. Memon M.I., Memon M.A. J. Viral Hepatitis. 9:2002;84.
2. Chan, L.; Das, S. K.; Reddy, T. J.; Poisson, C.; Proulx, M.; Pereira, O. ; Courchesne, M.; Roy, C.; Wang, W.; Siddiqui, A.; Yannopoulos, C. G.; Nguyen-Ba, N.; Labrecque, D.; Bethell, R.; Hamel, M.; Courtemanche-Asselin, P.; L'Heureux, L.; David, M.; Nicolas, O.; Brunette, S.; Bilimoria, D.; Bédard, J. Bioorg. Med. Chem. Lett. 2004, 14, preceding paper. doi:10.1016/j.bmcl.2003.10.067.
3. Piccininni S., Varaklioti A., Nardelli M., Dave B., Raney K.D., McCarthy J.E.G. J. Biol. Chem. 277:2002;45670.
4. Shirota Y., Luo H., Qin W., Kaneko S., Yamashita T., Kobayashi K., Murakami S. J. Biol. Chem. 277:2002;11149.
5. Dechantsreiter M.A., Planker E., Mathae B., Lohof E., Hoelzemann G., Jonczyk A., Goodman S.L., Kessler H. J. Med. Chem. 42:1999;3033.
6. Chan L., Reddy T.J., Proulx M., Das S.K., Pereira O., Wang W., Siddiqui A., Yannopoulos C., Poisson C., Turcotte N., Drouin A., Alaoui H.M.A., Bethell R., Hamel M., Bilimoria D., L'Heureux L., Nguyen-Ba N. J. Med. Chem. 46:2003;1283.
7. Bartenschlager R. Nat. Rev. Drug Discov. 1:2002;911.
8. All three analogues were studied by modeling each individual structure at their ionization state that could be reflected in aqueous conditions at ~pH 7. MOE (Chemical Computing Group Inc., Montreal, Canada) was used to build and energy minimize each structure with the MMFF94s force field using a gradient of 0.01 kcal/mol Å. The resulting minimized structures were used as starting points for conformational searching conducted by using the MOE implemented systematic conformational search tool. To visualize the conformational preference of each analogue, the first 200 lowest energy structures were examined for each of the representative 'closed' or 'open' shapes. The average energy difference between the 1st and 200th structure was approximately 3 kcal/mol Å.
9. Clore G.M., Gronenborn A.M. J. Magn. Reson. 48:1982;402.
10. Ni F., Scheraga H.A. Acc. Chem. Res. 27:1994;257.
11. Details of this experiment will be reported in a forthcoming publication.
12. 50 of 15 was within 62±10 μM.